EFN

For the hundreds of thousands of people that suffer from Multiple Sclerosis through out the world, the Cladribine and Fingolimod study results that are online at nejm.org and will be published in the New England Journal of Medicine bring the hope of non-injection or non-infusion methods of treatment.

Cladribine and Fingolimod studies implied that those suffering from the relapsing-remitting form of the disease benefited when given the oral forms of these drugs.
The Cladribine study took place over a 96 week time period and studied 1326 patients. Cladribine seemed to markedly reduce the rates of relapse and also showed a slow down in progression of the associated disabilities.

The Fingolimod study included 1272 patients, of which 1033 people actually finished. It showed that Fingolimod lowered the relapse rates and also slowed the progression of related disabilities.

Although these studies bring a new light on the treatment of MS, there are still questions that need to be answered as to the safety and long-term results and risks. Keep updating new information as it becomes available in the coming months and years.

These studies have possibly opened the door to easier treatment methods and hopefully a path to a cure one day.